ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 649

Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis

Fabian Proft1, Burkhard Muche1, Laura Spiller1, Valeria Rios Rodriguez1, Judith Rademacher1, Anne-Katrin Weber1, Susanne Lueders2, Mikhail Protopopov1, Inge Spiller1, Joachim Sieper3 and Denis Poddubnyy3,4, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 3Charité Universitätsmeidzin Berlin, Berlin, Germany, 4German Rheumatism Research Centre, Berlin, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: C-reactive protein (CRP), Disease Activity and axial spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity in patients with axial spondyloarthritis (axSpA). According to the treat-to-target (T2T) recommendations for SpA, and the ASAS/EULAR management recommendations for axSpA, the C-reactive protein (CRP)-based ASDAS is the preferred instrument for the assessment of disease activity in the process of making decision on modification of axSpA treatment in clinical routine. Currently, measurement of CRP by routine lab methods takes hours to days what challenges the feasibility of T2T approaches in clinical-routine and studies. The objective of this study was to compare the performance of the ASDAS based on a quickCRP assay (ASDAS-quick-CRP) with the ASDAS-routine-CRP and with the erythrocyte sedimentation rate (ESR)-based ASDAS in the assessment of disease activity in patients with axSpA.

Methods: This cross-sectional study was performed in patients referred with a suspicion of axSpA as part of the OptiRef study. Briefly, referred patients underwent an assessment of SpA features by a rheumatologist. CRP was measured in the central lab (routine turbidimetric assay, lowest detection level: 0.3mg/l) and locally by ESR and a quantitative quick-CRP test (QuickRead go®, Orion Diagnostica Oy, lowest detection level: 5mg/l, test duration approx. 2 min.). If the quick-CRP was below the limit of detection, the value of 2mg/l was used. In patients with the final diagnosis of axSpA, ASDAS-routine-CRP, ASDAS-quick-CRP and ASDAS-ESR were calculated.

Results: A total of 137 patients had available routine and quick CRP levels; 50 patients of them were diagnosed with axSpA. Mean±SD routine / quick CRP serum levels were 3.6±7.0 mg/l and 5.0±7.2 mg/l, respectively, in the entire group, and 6.2±8.3 mg/l and 7.4±8.4 mg/l, respectively, in patients with axSpA. There was no significant difference (p=0.11) in the mean values of ASDAS-CRP (2.7±1.0) and ASDAS-quick-CRP (2.8±1.0), while the ASDAS-ESR (2.9±1.0) was significantly higher than ASDAS-routine-CRP (p=0.02). In 46 of the 50 cases of axSpA (92%) the status scores for disease activity showed no difference between ASDAS-routine-CRP and ASDAS-quick-CRP – figure. For ASDAS-ESR compared to ASDAS-routine-CRP, only 33/48 patients (68.8%) were assigned to the same DAC.

Conclusion: ASDAS-quick-CRP performed similarly well to ASDAS-routine-CRP with an agreement on the status score for disease activity of 92%, that was clearly better than the agreement of 68.8% between ASDAS-ESR and ASDAS-routine-CRP. With a duration of approximately 2 minutes the quick-CRP test is, therefore, feasible for immediate decision making as a part of clinical routine or clinical trials.

Acknowledgements: The OptiRef project was supported by an unrestricted research grant from Novartis. The “QuickRead go” was provided free of charge by Orion Diagnostica Oy.


Disclosure: F. Proft, None; B. Muche, None; L. Spiller, None; V. Rios Rodriguez, None; J. Rademacher, None; A. K. Weber, None; S. Lueders, None; M. Protopopov, None; I. Spiller, None; J. Sieper, None; D. Poddubnyy, None.

To cite this abstract in AMA style:

Proft F, Muche B, Spiller L, Rios Rodriguez V, Rademacher J, Weber AK, Lueders S, Protopopov M, Spiller I, Sieper J, Poddubnyy D. Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/ankylosing-spondylitis-disease-activity-score-asdas-based-on-a-quick-quantitative-crp-assay-performs-similarly-well-to-asdas-based-on-conventional-crp-in-patients-with-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ankylosing-spondylitis-disease-activity-score-asdas-based-on-a-quick-quantitative-crp-assay-performs-similarly-well-to-asdas-based-on-conventional-crp-in-patients-with-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology